Inovio Pharmaceuticals, Inc. (INO)

10,57 +0,44 (+4,40%) Alla chiusura: 04:00PM EDT

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462
United States
267 440 4200
https://www.inovio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 122

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jacqueline E. Shea Ph.D.	CEO, President & Director	1,13M	N/D	1966
Mr. Peter D. Kies	Chief Financial Officer	810,2k	N/D	1963
Dr. Laurent M. Humeau Ph.D.	Chief Scientific Officer	794,08k	N/D	1967
Thomas Hong	Manager of Investor Relations	N/D	N/D	N/D
Mr. Robert L. Crotty J.D.	General Counsel & Chief Compliance Officer	N/D	N/D	1974
Mr. E. J. Brandreth MBA	Senior Vice President of Quality Assurance	N/D	N/D	N/D
Dr. Jeffrey Skolnik	Senior Vice President of Clinical Development	N/D	N/D	N/D
Mr. Robert J. Juba Jr.	Senior Vice President of Biological Manufacturing & Clinical Supply Management	N/D	N/D	N/D
Mr. Stephen Kemmerrer M.B.A., P.E.	Senior Vice President of Engineering Development	N/D	N/D	N/D
Mr. Shawn D. Bridy M.A., M.B.A.	Senior Vice President of Business Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Inovio Pharmaceuticals, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 3; diritti degli azionisti: 4; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.